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 CHANGEPOINT ANALYSIS OF HIV MARKER RESPONSES  
by 
JOY ROGERS 
Under the Direction of Pulak Ghosh 
ABSTRACT 
 
 We will propose a random changepoint model for the analysis of longitudinal CD4 and 
CD8 T-cell counts, as well as viral RNA loads, for HIV infected subjects following highly active 
antiretroviral treatment.  The data was taken from two studies, one of the Aids Clinical Group 
Trial 398 and one performed by the Terry Beirn Community Programs for Clinical Research on 
AIDS.  Models were created with the changepoint following both exponential and truncated 
normal distributions.  The estimation of the changepoints was performed in a Bayesian analysis, 
with implementation in the WinBUGS software using Markov Chain Monte Carlo methods.  For 
model selection, we used the deviance information criterion (DIC), a two term measure of model 
adequacy and complexity.  DIC indicates that the data support a random changepoint model with 
the changepoint following an exponential distribution.  Visual analyses of the posterior densities 
of the parameters also support these conclusions. 
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INTRODUCTION 
Human Immunodeficiency Virus (HIV) is a retrovirus that uses the enzyme reverse 
transcriptase to transcribe RNA into DNA.   Because transcription in the body generally occurs 
in the opposite direction – from DNA to RNA – retroviruses are highly susceptible to mutations.  
As a result, these viruses are very difficult to treat with antibiotics and thus far impossible to 
develop vaccines for (http://en.wikipedia.org/wiki/Hiv).  Thus, it is important to study HIV’s 
infection mechanisms in order to develop drug therapy programs that can slow the destruction of 
the body.  
HIV assaults the immune system by attacking the body’s cells, primarily CD4+ Helper T 
cells.  The term “Helper” is used because of the function of the CD4 cell; once the cells are 
activated, they divide quickly and emit cytokines, which are proteins that help the immune 
response. Along with CD4+ T cells, levels of CD8 T cells can also be used as a marker for HIV 
progression.  CD8 T cells, unlike CD4 cells, are not “Helper” T cells.  Instead, they are 
Cytotoxic T cells, which means they destroy cells that are virally infected 
(http://en.wikipedia.org/wiki/T_cells).  The final key definition is that of viral RNA.  As 
mentioned above, HIV is a retrovirus and contains RNA as the hereditary material.  This RNA 
contained in the retroviral particle is called viral RNA, since it is the template for further 
reproduction of viral cells (Kimball, 2005).  
Because the CD4+ cells are the primary target of HIV, the level of these cells in the body 
is often used as an indicator of the advancement of HIV infection (Wang, 2006).  
The levels of these cells in conjunction with the viral load (number of copies of HIV-1 RNA per 
millimeter of plasma) are widely used to predict progression of the disease to full-blown 
Acquired Immune Deficiency Syndrome (AIDS) and eventually, death (Kiuchi, 1995).  Since the 
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levels of these markers change from day-to-day, it is advisable to look at the general pattern over 
time in order to model the advancement of the disease.   
As the virus progresses, infected CD4+ cells are destroyed.  However, the body is 
simultaneously producing new CD4+ cells in order to produce antibodies and attempt to attack 
the virus.  It is generally accepted that immediately after infection, CD4+ cells rapidly multiply 
as an initial line of defense aga inst HIV; however, if the disease is left untreated, this increase in 
T-cell levels soon begins to decline as the virus attacks them (Gumel, 2001).  This decline can 
last up to several years, and often steepens just before the patient is diagnosed with AIDS.   
This progression can be slowed or reversed when the patient is treated.  When an 
individual begins on a drug program such as Highly Active Anti-Retroviral Therapy (HAART), 
the immune system can be restored to some extent because the drugs suppress the replication of 
the HIV cells and reduce the viral load (Ghosh and Vaida, 2006).  As a result of the medication, 
the CD4+ counts will begin to rise in a two stage process.  The first stage is a steep increase in 
CD4+ counts; the second, a more gradual increase (Deeks, 2004).  At least one historical study 
of this problem has estimated the time of the first increase to be around 12 weeks (Hunt, et al., 
2003); however, that model did not allow for variability between subjects, which can be done 
using a Bayesian approach to changepoint analysis.  This paper is concerned with estimating the 
changepoint for each patient at the time where the steep increase slows to the gradual increase of 
CD4+ levels.  We also extend our method to two other markers of HIV/AIDS – CD8 T-cells and 
viral RNA load.  
This thesis is organized in the following manner: Chapter 2 discusses changepoint 
analysis and its background as a statistical process.  This is followed by a description of the data 
sets used in Chapter 3, and a description in Chapter 4 of the measure used in model selection, the 
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Deviance Information Criterion.  Chapter 5 explains the methods used in testing different 
models, and Chapter 6 details the results of the testing.  The thesis concludes with a discussion of 
these results. 
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CHANGEPOINT ANALYSIS 
 In statistical analysis, it is often important to be able to determine if and when a change 
occurred in the behavior of data, especially time ordered data.  For example, it may be important 
to analyze a series of counts of violent crimes before and after a specific crime-fighting program 
was introduced to determine if the crime rate decreased (Loschi, et al, 2005).  Historically, 
methods such as control charts have been used to detect changes in data; however, these charts 
often fall short in detecting change if the change in the data is subtle.  Also, control charts control 
the point-wise error rate, as opposed to the change-wise error rate, so if a data set is large, the 
control chart may indicate that a point is outside the control limits even when no change has 
occurred, or vice-versa.  
Changepoint analysis is a powerful alternative method used to detect even slight changes 
in the distribution of time-ordered data. Changepoint analysis is especially beneficial because it 
can provide confidence levels and confidence intervals for the estimate of the point where the 
change occurs.  This helps to ensure that each change detected is real.  Also, changepoint 
analysis is reasonably robust to outliers, and can be adjusted to different types of data sets 
(attribute data, individual values, counts, and standard deviations, for example) easily.  Finally, 
because changepoint analysis automates the process of calculating new control limits following 
each change, it is much easier to use when dealing with large sets of historical data (Taylor, 
2000).   
There are some shortcomings when considering changepoint analysis.  Unlike some other 
tests, including control charts, it does not detect isolated abnormal points.  Also, because of the 
way changepoint analysis is performed (using a bootstrapping approach), it will not produce 
identical results each time it is performed due to the random selection of bootstrap samples.  This 
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can be overcome by increasing the number of iterations.  However, these inadequacies do not 
affect the use of the analysis in this paper, since approximately 50,000 iterations were used for 
each model. 
Changepoint analysis has been an active area of research to model progression of HIV 
and AIDS.  It is often used in determining the behavior of various biological markers, like CD4 
and CD8 T-cell counts and viral RNA load surrounding major events in the advancement of the 
disease.  Multiple changepoint testing has been used by Halpern to assess the possibility of 
genetic recombination in HIV sequences (2000).  Kiuchi, et al (1995) used a Bayesian 
changepoint analysis (specifically using an EM algorithm and MCMC) to estimate the time that a 
rapid decline of CD4 cells begins just prior to diagnosis with AIDS at approximately 1 year (with 
a standard deviation of 9 months).  Similarly, Lange, et al. (1992) developed models to find 
posterior distributions of time for CD4 T-cell numbers to reach a specified level (for example, 
near seroconversion or progression to AIDS).   
For our purposes, we use a Bayesian approach to create a model that allows variability 
between patients in their CD4 levels and changepoint times.  Each patient’s profile will be 
different (including CD4, CD8, and RNA counts), and the models used here with allow for 
random changepoints (Ghosh and Vaida, 2006).   
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DESCRIPTION OF DATA SETS 
Two data sets are used in the construction of the model – AIDS Clinical Trial Group 
(ACTG) 398 and a set taken from a study conducted by the Terry Beirn Community Programs 
for Clinical Research on AIDS. 
ACTG 398 was a study completed on 481 subjects with advanced stages of HIV 
infection.  The study was randomized, double-blind, and placebo-controlled, and compared four 
different highly active antiretroviral treatment (HAART) regimens.  All regimens in the study 
contained these antiretroviral drugs: abacavir (a nucleoside reverse transcriptase inhibitor – 
NRTI), adefovir dipivoxil (NRTI), efavirenz (a non-NRTI – NNRTI), and amprenavir (a 
protease inhibitor –PI).  Three of the four study groups were given a second PI (either saquinavir, 
indinavir, or nelfinavir), and the fourth was given a placebo.  The study was designed to compare 
the proportion of patients who had “virologic failure after 24 weeks of study between the double-
PI arms and the single-PI arm” (Ghosh and Vaida, 2006).    The data set used in this study 
contains measurements of CD4 cells, CD8 cells, and viral RNA loads for the subjects at weeks 0, 
2, 4, 8, 16, 24, 32, 40, and 48.   
The second data set, as mentioned previously, was taken from a study conducted by the 
Terry Beirn Community Programs for Clinical Research on AIDS.  The study was a multicenter, 
randomized, open-label, community based clinical trial of 467 patients.  These criteria required 
for inclusion into the study were as follows: at least 13 years of age; “having an AIDS defining 
condition or two CD4 lymphocyte counts of 300 cells or less per cubic millimeter, with either a 
positive serologic test for HIV or a working diagnosis of HIV infection” (Abrams, et al, 1994); 
and they had previously attempted (unsuccessfully) therapy with the drug zidovudine.  This drug 
must have led to either intolerance of the drug or progression of disease during therapy.  The trial 
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was designed to test the performance of two other drugs, didanosine or zalcitabine, and to see 
which of these dideoxynucleoside monotherapies performed better after zidovudine failed.  The 
patients were randomly assigned to receive either didanosine or zalcitabine, and allowed to 
switch from one drug to the other once during the course of the trial if intolerance developed.  
230 patients were assigned to didanosine, and 237 to zalcitabine, and the results of the study 
concluded that zalcitabine was at least as efficacious as didanosine in delaying progression and 
death, although neither drug offered substantial long-term benefit.  Further results and analysis 
are reported in the article by Abrams, et al.  The specific data set used here was taken from Guo 
& Carlin (2004), using the CD4 counts recorded at study entry, and again at the 2, 6, 12, and 18 
month visits. 
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DEVIANCE INFORMATION CRITERION FOR MODEL SELECTION 
It is necessary to have some criteria to select the best model when multiple models are 
tested.  In this study, we use deviance information criterion (DIC), which was proposed in 2002 
by Spiegelhalter, Best, Carlin, and van der Linde, and discussed by Berg, et al (2004).  This is a 
generalized version of the Akaike information criterion (AIC) and similar to the Bayesian 
information criterion (BIC), and like these, it compares a model based on measures of its 
adequacy and its complexity.  In order to accomplish this, the DIC uses two components: a 
Bayesian measure of model fit, D , and the effective number of parameters, pD.  The goodness of 
fit term, D , is defined as the posterior expectation of the deviance: 
)].|(ln2[)]([ || qq qq yfEDED yy -==  
D  is smaller for better- fitting models.   
 The second term, pD, is defined as the difference between the posterior mean of the 
deviance and the deviance evaluated at the posterior mean q of the parameters: 
( ) ).|(ln2)]|(ln2[])[()]([ ||| qqqqq qqq yfyfEEDDEDDp yyyD +-=-=-=  
This means that Dp  can be understood as the expected excess of the true over the estimated 
residual information in data y conditional on q; in other words, Dp  is the expected reduction in 
uncertainty due to estimation.   
 Putting the above two terms together and rearranging, we can define DIC as follows: 
DpD 2)(DIC += q . 
Myung, et al. (2005) gives three reasons why DIC is a desirable criterion for model 
selection in the Bayesian context.  The first is that, as mentioned above, the DIC is a Bayesian 
counterpart of the AIC (in fact, the two are asymptotically equivalent for normal linear models).  
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DIC improves over AIC in that its penalty term measures the complexity of order-constrained 
models, whereas AIC cannot discriminate between models with the same number of parameters 
but differing implementation of order-constraints.  Secondly, DIC does not require nesting of 
competing models.  Also, models do not have to be assumed true.  The third reason DIC works 
well is that it can be estimated by the posterior parameter samples generated by any Monte Carlo 
algorithm.  This allows DIC to be a superior criterion to the Bayes factor, another model 
selection standard (it is defined as the ratio of the marginal likelihood under one model to the 
marginal likelihood under a competing model).  The Bayes factor is very sensitive to the 
assumed prior distribution and can be difficult to compute and interpret for hierarchical models. 
By comparison, computing DIC via MCMC is almost trivial (Ghosh and Vaida, 2006).  
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METHODS 
This paper will consider a model of the form 
,)()( 321 ijiiijiijij ebKtKty ++-+-+= +- bbb                                (1) 
where ( )T1 ,..., iinii yyy =  is the response vector for individual i, and ( )T1 ,..., iinii ttt =  
is the corresponding vector of observation times, i = 1 ,…, n. Also, let Ki be the changepoint for 
individual i and ( )T321 ,, bbbb = be the vector of fixed effects.  Further define b1 as the overall 
intercept, and let b2 and b3 represent the overall slope before and after the changepoint Ki.   
Let  bi be the random effects for individual i, and eij be the error.  The random effects bi are 
assumed to follow a normal distribution with mean 0 and standard deviation 2bs ; likewise, we 
assume that eij follows a normal distribution.  These distributions can be written as 
bi ~ N(0, 2bs ), eij ~ N(0, 
2s ).                                             (2)   
One can take a more general model than (1) that includes additional random effects, but it does 
not give much benefit for the data sets we are analyzing.    
 Conditionally on the changepoints Ki, (1) follows a mixed-effects model, which can be 
written in general as 
 ,iiiii ebZXy ++= b                                                     (3) 
where Xi and Zi are ni x p and ni x q matrices of covariates for subject I, corresponding to the 
fixed and random effects, respectively.  Xi  includes baseline covariates, possibly time-varying 
covariates, such as treatment adherence, and the before-changepoint and after-changepoint 
vectors (t-Ki)- and (t-Ki)+; in general, Zi is a submatrix of Xi.  The random effects are given by 
(2), and the errors are assumed normal, ei ~ N(0, inI
2s ), independently of each other.   
The changepoints Ki are assumed to be random,  
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Ki ~ F( )g;× ,                                                            (4) 
independently of each other; F ( )g;×  is a parametric family of distributions (in this case, 
specifically exponential and truncated normal).  The equations (3), (4) define a general class of 
mixed effects random changepoint models for the biological markers.   
It is also important to note that each of the covariates used was transformed in order to 
stabilize the variance, improve normality of errors, and linearity of the mean.  The CD4 and CD8 
cell counts were placed on a square-root scale, and the RNA counts were adjusted using a 
logarithmic transformation.  
We fit the model using a fully Bayesian approach.  The full model specification includes 
prior distributions for the parameter q,  
 f(y, T, q) = f(y, T|q)f(q).                                                  (5) 
We assume the unknown parameters b , 2bs , 
2s , and g to be mutually independent in the prior. 
 The hyperparameters in the prior dis tributions were chosen so that the priors are 
uninformative.  We took 
b j ~ N(0, 1000),    independently                                           (6) 
s2 ~ IG(0.001, 0.001)                                                  (7) 
2
bs ~ IG(0.001, 0.001)                                                  (8) 
g ~ G(0.1, 0.1);                                                     (9)  
x ~ IG(a, b) means that 1/x has the Gamma distribution with mean a/b and variance a/b2, and 
G(a,b) denotes a Gamma distribution with parameter a, b.   
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RESULTS 
For the first data set (from ACTG 398), we considered several models for yij, as follows: 
· Model 1:  Uses the CD4 cell level as the response, with the changepoint 
following an exponential distribution, Ki ~ Exp(l) 
· Model 2: Same as Model 1, but with the changepoint following a truncated 
normal distribution, Ki ~ TN (2,0.1)I(0,) 
· Model 3: Same as Model 1, but with CD8 level as the response 
· Model 4: Same as Model 2, but with CD8 level as the response 
· Model 5: Same as Model 1, but with log10 HIV-1 RNA level as the response 
· Model 6: Same as Model 2, but with log10 HIV-1 RNA level as the response 
For data set two, the same models as Model 1 and Model 2 were used.  All models have 
a random changepoint for the responses.   
We implemented the model in WinBUGS, using Markov chain Monte Carlo sampling 
from the posterior distribution (see Appendix A for further information on WinBUGS 
implementation) .  It is important to determine the number of iterations necessary to achieve 
convergence to the stationary distribution. For this study, it was concluded that 25,000 iterations 
were sufficient for the burn- in period.   
Table 1 contains the model comparison for the different models used, including the DIC 
value, the effective number of parameters (or effective degrees of freedom) pD, and an estimate 
for K , the posterior mean of the changepoint, and its standard deviation for the 455 subjects, in 
weeks. Models 1 – 6 deal with the first data set (from ACTG 398).  Models 7 and 8 use the data 
from set two.  For data set 1, the two models using the CD8 counts (models 3 and 4) have the 
highest DIC values at 15689.4 and 15791.8, respectively, so they have the least support.  Using 
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CD4 as the response reduces the DIC values to 12328.9 for model 1 and 12332.3 for model 2.  
There is a large improvement, however, when using RNA as the response, and we get 8075.3 and 
8431.5 as the DIC values for models 5 and 6 respectively.  The number of effective degrees of 
freedom pD is smallest for model 3.  All of the models confirm that when Ki follows the 
exponential distribution, the model is more adequate. All six models for data set 1 have similar 
posterior means of the changepoint values, which is placed, on average, at 3.7 weeks, with 
standard deviation of 0.39 weeks.   
  DIC pD K (SD) 
Model 1 12328.9 665.5 3.769 (0.03) 
Model 2 12332.3 692.5 3.405 (0.11) 
Model 3 15689.4 551.3 3.964 (0.18) 
Model 4 15791.8 562.6 3.408 (0.11) 
Model 5 8075.3 588.4 4.364 (0.21) 
Model 6 8431.5 612.4 3.448 (0.11) 
Table 1. Model comparison using DIC values for data set 1.  
 
Similar to data set 1, for the second data set, model 7 (which uses the exponential 
distribution for the changepoints) is superior to model 8 (which uses the truncated normal 
distribution).  Model 7 does have a smaller pD value at 375.5.  The posterior mean of the 
changepoint value is placed, on average, at 3.7 weeks, with a standard deviation of 0.43 weeks.   
 
  DIC pD K (SD) 
Model 7 6117.6 375.5 3.988 (0.18) 
Model 8 6507.5 509.2 3.375 (0.10) 
Table 2. Model Comparison using DIC values for data set 2. 
 
For all models, DIC gives credible values with positive and meaningful pD  values.  
Figures 1 through 8 below show the density plots of the posterior means for the 
changepoints Ki for each of the models.  
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Figure 1. Plot of the posterior mean values of the changepoints Ki of model 1 
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Figure 2. Plot of the posterior mean values of the changepoints Ki of model 2 
 
 
  
15 
 
Histogram - Data Set 1 (CD8/K~exp)
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Figure 3. Plot of the posterior mean values of the changepoints Ki of model 3 
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Figure 4. Plot of the posterior mean values of the changepoints Ki of model 4 
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Figure 5. Plot of the posterior mean values of the changepoints Ki of model 5 
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Figure 6. Plot of the posterior mean values of the changepoints Ki of model 6 
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Figure 7. Plot of the posterior mean values of the changepoints Ki of model 7 
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Figure 8. Plot of the posterior mean values of the changepoints Ki of model 8 
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The parameter estimates for each model are shown in Tables 2-5. 
Model 1   Model 2 
Parameter 
Estimate 
Posterior 
Mean 
95% Posterior 
Interval  
Parameter 
Estimate 
Posterior 
Mean 
95% Posterior 
Interval 
b1 15.19 (14.7, 15.67)  b1 14.97 (14.47, 15.45) 
b2 0.021 (0.017, 0.025)  b2 -0.03345 (-0.037, -0.030) 
b3 -0.070 (-0.082, -0.058)  b3 0.1149 (0.102, 0.129) 
sb 5.168 (4.832, 5.528)  sb 5.129 (4.795, 5.488) 
s 1.959 (1.897, 2.023)  s 1.855 (1.798, 1.915) 
Table 3. Parameter estimates, posterior means, and 95% posterior intervals for Models 1 and 2 
 
Model 3   Model 4 
Parameter 
Estimate 
Posterior 
Mean 
95% Posterior 
Interval  
Parameter 
Estimate 
Posterior 
Mean 
95% Posterior 
Interval 
b1 29.4 (28.74, 30.04)  b1 29.73 (29.09, 30.38) 
b2 -0.029 (-0.034, -0.023)  b2 0.032 (0.025, 0.039) 
b3 0.047 (0.028, 0.066)  b3 -0.162 (-0.187, -0.136) 
sb 6.711 (6.263, 7.195)  sb 6.701 (6.252, 7.186) 
s 3.658 (3.543, 3.775)  s 3.719 (3.603, 3.838) 
Table 4. Parameter estimates, posterior means, and 95% posterior intervals for Models 3 and 4 
 
Model 5   Model 6 
Parameter 
Estimate 
Posterior 
Mean 
95% Posterior 
Interval  
Parameter 
Estimate 
Posterior 
Mean 
95% Posterior 
Interval 
b1 3.977 (3.83, 4.07)  b1 3.952 (3.86, 4.046) 
b2 0.006 (0.005, 0.006)  b2 0.009 (0.008, 0.010) 
b3 -0.027 (-0.030, -0.024)  b3 -0.035 (-0.038, -0.031) 
sb 0.928 (0.861, 1.001)  sb 0.912 (0.844, 0.984) 
s 0.765 (0.744, 0.787)  s 0.772 (0.751, 0.793) 
Table 5. Parameter estimates, posterior means, and 95% posterior intervals for Models 5 and 6 
 
Model 7   Model 8 
Parameter 
Estimate 
Posterior 
Mean 
95% Posterior 
Interval  
Parameter 
Estimate 
Posterior 
Mean 
95% Posterior 
Interval 
b1 7.088 (6.598, 7.587)  b1 7.171 (6.756, 7.607) 
b2 0.004 (-0.046, 0.056 )  b2 0.059 (0.036, 0.081) 
b3 -0.220 (-0.352, -0.086)  b3 -0.373 (-0.446, -0.300) 
sb 4.512 (4.208, 4.833)  sb 4.537 (4.239, 4.862) 
s 1.86 (1.766, 1.957)  s 1.841 (1.746, 1.942) 
Table 6. Parameter estimates, posterior means, and 95% posterior intervals for Models 7 and 8 (data set 2) 
 
 
Each pair of models gives similar estimates for the parameters.  Of particular interest is 
Table 4, which gives the estimates for Models 5 and 6, the models for data set 1 that gave the 
lowest DIC values.  Specifically, in Model 5, the initial slope (b2) is of about 0.006 (in log10 
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RNA per week), and is significantly positive, since the 95% posterior interval does not contain 0.   
The subsequent slope (b3), following the changepoint, is much smaller, as expected.  Its negative 
value indicates that the longitudinal trajectory is headed down after the changepoint.  The same 
observations hold true for model 6.  For the second data set, we see in Table 5 that similar 
conclusions can be drawn about models 7 and 8.   
We can also perform a visual inspection the beta parameters by looking at the posterior 
density plots, seen in the figures below.   
beta[1] sample: 25000
   14.0    14.5    15.0    15.5    16.0
    0.0
    0.5
    1.0
    1.5
    2.0
             
beta[2] sample: 25000
   0.01   0.015    0.02   0.025
    0.0
  100.0
  200.0
  300.0
 
beta[3] sample: 25000
   -0.1   -0.08   -0.06
    0.0
   20.0
   40.0
   60.0
   80.0
 
Figures 9 - 11: Posterior density plots of b1, b2, and b3 for Model 1 
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beta[1] sample: 25000
   14.0    15.0    16.0
    0.0
    0.5
    1.0
    1.5
    2.0
 
beta[2] sample: 25000
 -0.045   -0.04  -0.035   -0.03
    0.0
  100.0
  200.0
  300.0
 
beta[3] sample: 25000
   0.08     0.1    0.12    0.14
    0.0
   20.0
   40.0
   60.0
 
Figures 12-14: Posterior density plots of b1, b2, and b3 for Model 2 
 
beta[1] sample: 25000
   28.0    29.0    30.0
    0.0
    0.5
    1.0
    1.5
 
beta[2] sample: 25000
  -0.04   -0.03   -0.02
    0.0
   50.0
  100.0
  150.0
  200.0
 
beta[3] sample: 25000
    0.0    0.02    0.04    0.06    0.08
    0.0
   20.0
   40.0
   60.0
 
Figures 15-17: Posterior density plots of b1, b2, and b3 for Model 3 
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beta[1] sample: 25000
   28.0    29.0    30.0
    0.0
    0.5
    1.0
    1.5
 
beta[2] sample: 25000
  -0.06   -0.05   -0.04   -0.03
    0.0
   50.0
  100.0
  150.0
 
beta[3] sample: 25000
    0.0    0.05     0.1
    0.0
   10.0
   20.0
   30.0
   40.0
 
Figures 18-20: Posterior density plots of b1, b2, and b3 for Model 4 
 
beta[1] sample: 23000
    3.7     3.8     3.9     4.0     4.1
    0.0
    2.5
    5.0
    7.5
   10.0
 
beta[2] sample: 23000
  0.004   0.005   0.006   0.007
    0.0
  500.0
1.00E+3
 1500.0
 
beta[3] sample: 23000
 -0.035   -0.03  -0.025
    0.0
  100.0
  200.0
  300.0
 
Figures 21 - 23: Posterior density plots of b1, b2, and b3 for Model 5 
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beta[1] sample: 25000
    3.6     3.8     4.0
    0.0
    2.5
    5.0
    7.5
   10.0
 
beta[2] sample: 25000
  0.006   0.008    0.01
    0.0
  200.0
  400.0
  600.0
  800.0
 
beta[3] sample: 25000
 -0.045   -0.04  -0.035   -0.03
    0.0
  100.0
  200.0
  300.0
 
Figures 24 - 26: Posterior density plots of b1, b2, and b3 for Model 6 
 
beta[1] sample: 25000
    6.0     7.0     8.0
    0.0
    0.5
    1.0
    1.5
    2.0
 
beta[2] sample: 25000
   -0.1   -0.05     0.0    0.05
    0.0
   10.0
   20.0
   30.0
 
beta[3] sample: 25000
   -0.6    -0.4    -0.2
    0.0
    2.0
    4.0
    6.0
    8.0
 
Figures 27 - 29: Posterior density plots of b1, b2, and b3 for Model 7 
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beta[1] sample: 25000
    6.0     6.5     7.0     7.5     8.0
    0.0
    0.5
    1.0
    1.5
    2.0
 
beta[2] sample: 25000
    0.0   0.025   0.075     0.1
    0.0
   10.0
   20.0
   30.0
   40.0
 
beta[3] sample: 25000
   -0.6    -0.5    -0.4    -0.3
    0.0
    5.0
   10.0
   15.0
 
Figures 30 - 32: Posterior density plots of b1, b2, and b3 for Model 8 
 
These density plots appear to be smooth and unimodel for most cases.  
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DISCUSSION 
 This paper discusses a random changepoint model for HIV immunological markers, 
including CD4, CD8, and viral RNA levels at times surrounding the initiation of HAART 
therapy.  The model was fitted in WinBUGS using a Bayesian approach, which allows flexibility 
in model specification.  We chose noninformative priors for the model parameters and variance 
components.  The model selection was directed by use of DIC, which combines a measure of 
goodness-of- fit as well as a measure of model complexity.  DIC has limitations, but in our case 
provided credible values. 
 Our analysis confirms previous findings that in subjects with viral suppression the CD4, 
CD8 and viral RNA loads show a two-step change in their levels (an increase for CD4 and CD8 
cell counts, and a decrease for viral RNA).  We can improve prediction by allowing the 
changepoint of the rebound to vary between subjects.  This also reinforces the idea that the T-cell 
rebound process may follow the viral load process, where the steep decline lasts for two weeks 
after beginning treatment (Ghosh and Vaida, 2006).  Future research into the joint modeling of 
T-cell counts and RNA loads may be needed to further describe the association between the two.       
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APPENDIX A 
 
Implementation Using WinBUGS 
  
Following is a copy of the WinBUGS code to implement the methods described in this paper. 
 
When Ki follow the exponential distribution: 
 
model{ 
 
# Level 1: Longitudinal data with changepoint K[i] 
 
for (i in 1:N) { 
    for (j in 1:M) { 
       Y[i,j] ~ dnorm(muy[i,j], tauY) 
       muy[i,j] <- beta[1]+ beta[2]*(t[j]-K[i])*min(K[i],t[j]) + beta[3]*(t[j]-K[i])*step(t[j]-K[i]) + b[i] 
 
        
} 
 
 
 
} 
for ( i in 1:N){ 
# Level 2: random effects 
b[i] ~ dnorm(0,invSigma) 
 
K[i] ~ dexp(lambda) 
 
} 
 
 
# Level 3: priors 
    beta[1:3]~dmnorm(zero3[],invSigmabeta[,]) 
 
 tauY~dgamma(0.1,0.1) 
 #tauYnew~dgamma(0.1,0.1) 
 invSigma ~ dgamma(0.1,0.1) 
  
  
# derived variables 
for (i in 1:N){ for(j in 1:M){  
res[i,j] <- Y[i,j]-muy[i,j]  
tt[i,j] <- t[j] 
}} 
sigmaY <- 1/sqrt(tauY) 
sigmab <- 1/sqrt(invSigma) 
meanK <- mean(K[]) 
} 
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When Ki follow the truncated normal distribution: 
 
model{ 
 
# Level 1: Longitudinal data with changepoint K[i] 
 
for (i in 1:N) { 
    for (j in 1:M) { 
       Y[i,j] ~ dnorm(muy[i,j], tauY) 
       muy[i,j] <- beta[1]+ beta[2]*(t[j]-K[i])*min(K[i],t[j]) + beta[3]*(t[j]-K[i])*step(t[j]-K[i]) + b[i] 
 
        
} 
 
 
 
} 
for ( i in 1:N){ 
# Level 2: random effects 
b[i] ~ dnorm(0,invSigma) 
 
K[i] ~ dnorm(2,0.1)I(0, ) 
 
} 
 
 
# Level 3: priors 
    beta[1:3]~dmnorm(zero3[],invSigmabeta[,]) 
 
 tauY~dgamma(0.1,0.1) 
 #tauYnew~dgamma(0.1,0.1) 
 invSigma ~ dgamma(0.1,0.1) 
  
  
# derived variables 
for (i in 1:N){ for(j in 1:M){  
res[i,j] <- Y[i,j]-muy[i,j]  
tt[i,j] <- t[j] 
}} 
sigmaY <- 1/sqrt(tauY) 
sigmab <- 1/sqrt(invSigma) 
meanK <- mean(K[]) 
} 
